Tags Archive Navigation
icon
-
Media ReleaseNovartis, encore un fort trimestre: croissance à deux chiffres des ventes et expansion de la marge core1; hausse des prévisions de chiffre d’affaires et de résultat en 2019; Beovu lancé aux USA
-
Media ReleaseNovartis delivered another strong quarter with double digit sales growth and core1 margin expansion; 2019 sales and profit guidance raised; Beovu launched in US
-
Media ReleaseNovartis verzeichnet ein weiteres starkes Quartal mit zweistelligem Umsatz-wachstum und höherer Kerngewinnmarge1; Umsatz- und Gewinnerwartung für 2019 angehoben; US-Einführung von Beovu
-
Media ReleaseNovartis announces AVXS-101 intrathecal study update
-
Media ReleaseNovartis Cosentyx® shows encouraging results versus Humira®* from first-of-its-kind head-to-head trial in psoriatic arthritis
-
Media ReleaseNew Novartis medicine Adakveo® (crizanlizumab) approved by FDA to reduce frequency of pain crises in individuals living with sickle cell disease
-
Media ReleaseNovartis to acquire The Medicines Company for USD 9.7 bn, adding inclisiran, a potentially transformational investigational cholesterol-lowering therapy to address leading global cause of death
-
Media ReleaseNovartis appoints Dr. Klaus Moosmayer as Chief Ethics Risk and Compliance Officer
-
Media ReleaseSOLAR-1 trial of Novartis investigational alpha-specific PI3K inhibitor BYL719 (alpelisib) meets primary endpoint in HR+/HER2- advanced breast cancer with PIK3CA mutation
-
Media ReleaseAlcon announces voluntary global market withdrawal of CyPass Micro-Stent for surgical glaucoma
-
Media ReleaseNovartis to divest the Sandoz US dermatology business and generic US oral solids portfolio to Aurobindo
-
Media ReleaseNovartis erzielt im dritten Quartal starkes Wachstum und treibt Innovationen wie fortschrittliche Therapieplattformen voran, um das zukünftige Wachstum zu beschleunigen
Pagination
- ‹ Previous page
- 1
- …
- 9
- 10
- 11
- 12
- 13
- 14
- 15
- 16
- › Next page